Press Releases

Petauri, a leading purpose-built pharmaceutical services platform, announced today the launch of its new channel strategy offering. This expanded service will be part of the organization's consulting arm, Petauri Advisors, which focuses on pricing, reimbursement, access, and value demonstration. The Channel Strategy team will collaborate with emerging pharmaceutical manufacturers to define the optimal distribution path and flow for specific drugs, ensuring they reach patients an

Foresee Pharmaceuticals announced today the acceptance of an abstract for presentation at the prestigious American Society of Clinical Oncology, Genitourinary (ASCO-GU) Cancers Symposium conference, which will be held at the Moscone Convention Center West in San Francisco, CA, from February 13 to 15, 2025. The abstract is titled: "Global, Phase 3, Open-Label, Single-Arm Studies to Evaluate the Efficacy, Safety, and Pharmacokinetics of FP-014, 11.25 mg (Triptorelin Mesylate Inje

Global biotechnology leader CSL and sa-mRNA pioneer Arcturus Therapeutics today announced that the European Commission has granted marketing authorization for KOSTAIVE ® (ARCT-154), a self-amplifying mRNA COVID-19 vaccine, for individuals 18 years and older. KOSTAIVE is the first sa-mRNA COVID-19 vaccine to receive approval from the European Commission (EC). KOSTAIVE is currently marketed in Japan against COVID-19. The European Commission approval follows a positive opinion adop

IASO Biotherapeutics ("IASO Bio"), a biopharmaceutical company focused on the discovery, development, manufacturing, and commercialization of innovative cell therapies and biologics, today announced that the Hong Kong Department of Health (DOH) has officially accepted the New Drug Application (NDA) for Equecabtagene Autoleucel. This treatment is indicated for patients with relapsed and/or refractory multiple myeloma (R/R MM) who have received three or more prior lines of therapies.

Moleculin Biotech, Inc., a late-stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses, today announced it has received U.S. Food and Drug Administration ("FDA") feedback and guidance on its IND amendment that has allowed a reduction in the size of its Phase 3 pivotal trial protocol evaluating Annamycin in combination with Cytarabine (also known as "Ara-C" and for which the combination of Annamycin and Ara-C is ref

Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the reference listed drug, Evoclin®2 Foam, 1%, of Mylan Pharmaceuticals Inc. According to IQVIA™ sales data for the 12-month period ending December 2024, the Evoclin® Foam, 1% market3 achieved annual sales of approximately $5.8 million*. About Glenmark Ph

AbbVie and Xilio Therapeutics, Inc. a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced a collaboration and option-to-license agreement to develop novel tumor-activated, antibody-based immunotherapies, including masked T-cell engagers, leveraging Xilio’s proprietary technology. Xilio has developed a proprietary, clinically-validated platform technology for tumor-activated bio

NLS Pharmaceutics Ltd. a Swiss clinical-stage biopharmaceutical company focused on the discovery and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. ("Kadimastem") (TASE: KDST), a clinical-stage cell therapy company developing and manufacturing "off-the-shelf" allogeneic cell products for the treatment of neurodegenerative diseases and potential cure for diabetes, are on a mission to create a leading biotechnol

TC BioPharm PLC a clinical-stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and other indications, today announced the first Cohort B patient in the ACHIEVE Phase 2B UK clinical trial, evaluating TCB008 in Acute Myeloid Leukemia, has completed the full dosing regiment. The ACHIEVE trial is an open-label Phase II study dedicated to evaluating the efficacy and safety of TCB008. This trial is focused on assessing the treatment's eff

Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical and nutraceutical excipients, today launches its refreshed coatings platform for pharma and nutraceuticals. Bringing together two ranges – Tabshield® ready-to-use film coating systems and ReadiLYCOAT® plant-based ready-to-use coating systems – the platform represents Roquette’s widest collection of versatile and sustainable coating products to date, each designed to address